Structure Therapeutics (NASDAQ:GPCR) Sets New 12-Month Low – Here’s Why

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) reached a new 52-week low during trading on Monday . The stock traded as low as $22.22 and last traded at $21.90, with a volume of 216488 shares changing hands. The stock had previously closed at $23.77.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on GPCR. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Structure Therapeutics in a research report on Thursday, December 19th. JMP Securities reaffirmed a “market outperform” rating and issued a $91.00 price target on shares of Structure Therapeutics in a report on Wednesday, December 18th. Finally, Stifel Nicolaus initiated coverage on Structure Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price objective for the company. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $81.29.

Structure Therapeutics Stock Performance

The company has a market cap of $1.20 billion, a price-to-earnings ratio of -28.42 and a beta of -2.75. The company’s fifty day moving average is $27.37 and its two-hundred day moving average is $34.02.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. ANTIPODES PARTNERS Ltd boosted its holdings in Structure Therapeutics by 115.0% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock valued at $28,000 after purchasing an additional 553 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Structure Therapeutics by 4,155.6% in the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock worth $31,000 after buying an additional 1,122 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in Structure Therapeutics during the fourth quarter worth about $34,000. FNY Investment Advisers LLC purchased a new position in Structure Therapeutics during the fourth quarter valued at approximately $40,000. Finally, Assetmark Inc. raised its position in Structure Therapeutics by 120.0% during the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock valued at $58,000 after acquiring an additional 719 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.